Continuous Glucose Monitoring for Post-discharge Diabetes Management
Icahn School of Medicine at Mount Sinai
Summary
This is an investigator initiated prospective, randomized controlled trial which aims to compare two groups of patients with either type 2 or steroid-induced diabetes who are discharged with insulin. The intervention group will use the Libre 3 Plus continuous glucose monitoring (CGM) system at discharge, while the control group will use blinded CGM and fingerstick monitoring. Both the intervention and control groups will wear the sensor for 28 days post discharge and participate in telehealth diabetes management visits. The target enrollment for the study is 65 participants and participants are expected to be in the study for up to 35 days.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Adult 18 years or older. * Inpatient treatment for type 2 or steroid induced diabetes during hospitalization, with plan for insulin use after discharge. Exclusion Criteria: * Type 1 diabetes * Plan for discharge to rehabilitation/skilled nursing/hospice facility * Contra-indication to sensor placement * Pregnancy
Interventions
- DeviceLibre 3 Plus continuous glucose monitoring (CGM) system
Use of unmasked CGM after discharge
- DeviceBlinded Continuous Glucose Monitoring
Masked CGM
- BehavioralFinger stick
Self-monitoring blood glucose
Location
- Icahn School of Medicine at Mount SinaiNew York, New York